ClinicalTrials.gg
CompletedNCT03124108Updated Sep 24, 2019Results posted

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

A Phase 2 interventional study of Elafibranor 80 mg and Elafibranor 120 mg in Primary Biliary Cholangitis (PBC), sponsored by Genfit. Completed at 24 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
34th of 65
45 · median 46
Started
2017
with 7 others
Phase 2
34 of 83
2 open now
Registered
36th of 83
by date

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 34th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 36th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).

03

Conditions studied

  • Primary Biliary Cholangitis (PBC)

Keywords

  • Elafibranor
  • Primary Biliary Cholangitis
  • Alkaline phosphatase
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have provided written
  2. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:

    • History of elevated ALP levels for at least 6 months prior to Day 0 (randomization visit)
    • Positive Anti-Mitochondrial Antibodies (AMA) titers (> 1/40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies
    • Liver consistent with PBC
  3. ALP >= 1.67x (ULN)
  4. Taking UDCA for at least 12 months (stable dose for ≥ 6 months) prior to screening visit
  5. : Females participating in this study must be of non- or must be using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of other concomitant liver diseases
  2. Screening creatine phosphokinase (CPK) > (ULN)
  3. Screening (ALT) or aspartate aminotransferase (AST) > 5 ULN
  4. Screening total > 2 ULN
  5. Screening serum creatinine > 1.5 mg/dl
  6. Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney damage or estimated [eGFR] of less than 60 mL/min/1.73 m\^2).
  7. Patients with moderate or severe hepatic impairment (defined as B/C)
  8. count \<150 X 10\^3/microliter
  9. Albumin \<3.5 g/dL
  10. Presence of clinical complications of PBC or hepatic decompensation
  11. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating
  12. Known history of (HIV) infection
  13. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Study subjects will take two tablets per day orally before breakfast with a glass of water each morning

    Drug: Placebo

  • Active comparator
    Elafibranor 80 mg

    Study subjects will take two tablets per day orally before breakfast with a glass of water each morning

    Drug: Elafibranor 80 mg

  • Active comparator
    Elafibranor 120 mg

    Study subjects will take two tablets per day orally before breakfast with a glass of water each morning

    Drug: Elafibranor 120 mg

Interventions

  • Two coated tablets daily for 12 weeks

    Also known as: GFT505

  • Two coated tablets daily for 12 weeks

    Also known as: GFT505

  • DrugPlacebo

    Two coated tablets daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint)

    Relative change from baseline is in serum ALP levels at Week 12 (endpoint) were reported. Relative change from baseline is defined as percentage (%) change from baseline to endpoint.

    Time frame: Baseline, Week 12 (Endpoint)

Secondary outcomes

  1. Percentage of Participants With Response Defined by Composite Risk Scores (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] Within Normal Limits at Endpoint, and Greater Than [>] 15% ALP Reduction From Baseline to Endpoint)

    Percentage of participants with response defined by Composite Risk Scores (ALP Less than \[\<\] 1.67 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 15% ALP reduction from baseline to Endpoint) was reported.

    Time frame: Up to Week 12 (Endpoint)

  2. Percentage of Participants With Response Defined by Composite Risk Scores (ALP < 2 * Upper Limit of Normal at Endpoint, Total Bilirubin Within Normal Limits at Endpoint, and > 40% ALP Reduction From Baseline to Endpoint)

    Percentage of participants with response defined by composite risk scores (ALP \< 2 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 40% ALP reduction from baseline to endpoint) was reported.

    Time frame: Up to Week 12 (Endpoint)

  3. Percentage of Participants With Response Based on PARIS I Risk Score at Endpoint

    Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (\<=) 3 \* ULN and aspartate aminotransferase (AST) \<= 2 \* ULN and bilirubin within normal limits.

    Time frame: At Week 12 (Endpoint)

  4. Percentage of Participants With Response Based on PARIS II Risk Score at Endpoint

    Percentage of participants with response based on Paris II risk score was defined as ALP \<= 1.5 \* ULN and AST \<= 1.5 \* ULN and bilirubin within normal limits.

    Time frame: At Week 12 (Endpoint)

  5. Percentage of Participants With Response Based on Toronto I Risk Score at Endpoint

    Percentage of participants with response based on Toronto I risk score was defined as ALP \<= 1.67 \*ULN.

    Time frame: At Week 12 (Endpoint)

  6. Percentage of Participants With Response Based on Toronto II Risk Score at Endpoint

    Percentage of participants with response based on Toronto II risk scores was defined as ALP \<= 1.75 \* ULN.

    Time frame: At Week 12 (Endpoint)

  7. Median Percentage Risk as Assessed by United Kingdom-Primary Biliary Cholangitis (UK-PBC) Risk Total Score at Endpoint

    UK-PBC risk score at endpoint estimated that the median percentage risk that a participant treated with ursodeoxycholic acid (UDCA) will develop liver failure requiring liver transplant in 5, 10 and 15 years. UK-PBC score was calculated at each of the 3 survivor functions 1-baseline survival function\^exp(0.0287854\*\[alpEPxuln-1.722136304\] - 0.0422873\*\[{(altastEPxuln/10)\^-1} - 8.675729006\] + 1.4199 \* \[ln{bilEPxuln /10}+2.709607778\] -1.960303\*\[albxlln -1.17673001\]-0.4161954\*\[ pltxlln -1.873564875\]). Where: Baseline survivor function=0. 982 (at 5 years); 0. 941 (at 10 years); 0.893 (at 15 years). alpEPxuln = ALP at endpoint/upper level normal ALP; altastEPxuln=(ALT, AST) at endpoint/upper level normal of the value; bilEPxuln=bilirubin at endpoint/upper level normal bilirubin; albxlln=albumin at baseline/albumin lower level normal; pltxlln=platelet count at baseline/ platelet count lower level normal.

    Time frame: At Week 12 (Endpoint)

  8. Percentage of Participants With Response Defined by 10, 20 and 40 Percent Reduction in Alkaline Phosphatase

    Percentage of participants with response (defined by at least 10%, 20%, and 40% decrease in ALP from baseline to Endpoint) reported.

    Time frame: At Week 12 (Endpoint)

  9. Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Endpoint

    The response was defined by normalized ALP levels (ALP ULN 105 units per liter \[U/L\] for females, 129 U/L for males) at endpoint.

    Time frame: At Week 12 (Endpoint)

  10. Percentage of Participants With Response Defined by Normalized Bilirubin (BIL) at Endpoint

    The response was defined by normalized BIL levels (BIL ULN \<1.20 milligram per deciliter \[mg/dL\]) at endpoint.

    Time frame: At Week 12 (Endpoint)

  11. Percentage of Participants With Response Defined by Normalized Albumin (ALB) Levels at Endpoint

    The response was defined by normalized ALB levels (3.5-5.2 gram per deciliter \[g/dL\] for ages 18-60 years; 3.2-4.6 g/dL for ages 61-91 years) at endpoint.

    Time frame: At Week 12 (Endpoint)

  12. Change From Baseline in Alanine Aminotransferase (ALT) Levels at Endpoint

    Change from baseline in ALT levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  13. Change From Baseline in Aspartate Aminotransferase (AST) Levels at Endpoint

    Change from baseline in AST levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  14. Change From Baseline in Gamma-glutamyl Transferase (GGT) Levels at Endpoint

    Change from baseline in GGT levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  15. Change From Baseline in 5 Prime (') Nucleotidase Levels at Endpoint

    Change from baseline in 5' nucleotidase levels at endpoint was reported. 5' nucleotidase is an enzyme used as a biomarker of hepatobiliary cholestasis and is less sensitive but more specific than GGT and ALP.

    Time frame: Baseline, Week 12 (Endpoint)

  16. Change From Baseline in Total Bilirubin (BIL) Levels at Endpoint

    Change from baseline in total BIL levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  17. Change From Baseline in Conjugated Bilirubin Levels at Endpoint

    Change from baseline in conjugated bilirubin levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  18. Change From Baseline in Albumin Levels at Endpoint

    Change from baseline in albumin levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  19. Change From Baseline in Cholesterol Levels at Endpoint

    Change from baseline in cholesterol levels at endpoints was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  20. Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol Levels at Endpoint

    Change from baseline in LDL-cholesterol at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  21. Change From Baseline in High-density Lipoprotein (HDL) Cholesterol Levels at Endpoint

    Change from baseline in HDL-cholesterol levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  22. Change From Baseline in Triglycerides Levels at Endpoint

    Change from baseline in triglycerides levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  23. Change From Baseline in Total Free Bile Acid Levels at Endpoint

    Change from baseline in total free bile acid levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  24. Change From Baseline in Total Conjugated Bile Acid Levels at Endpoint

    Change from baseline in total conjugated bile acid levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  25. Change From Baseline in Total Bile Acid Levels at Endpoint

    Change from baseline in total bile acid levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  26. Change From Baseline in 7 Alpha-hydroxy-4-cholesten-3-one Levels at Endpoint

    Change from baseline in 7 alpha-hydroxy-4-cholesten-3-one levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  27. Change From Baseline in Fibroblast Growth Factor-19 Levels at Endpoint

    Change from baseline in fibroblast growth factor-19 levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  28. Change From Baseline in Immunoglobulin M (IgM) Levels at Endpoint

    Change from baseline in IgM levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  29. Change From Baseline in Tumor Necrosis Factor Levels at Endpoint

    Change from baseline in tumor necrosis factor levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  30. Change From Baseline in Transforming Growth Factor Beta Levels at Endpoint

    Change from baseline in transforming growth factor beta levels at endpoint was reported,

    Time frame: Baseline, Week 12 (Endpoint)

  31. Change From Baseline in Interleukin 6 Levels at Endpoint

    Change from baseline in interleukin 6 levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  32. Change From Baseline in Plasminogen Activator Inhibitor-1 Antigen (AG) Levels at Endpoint

    Change from baseline in plasminogen activator inhibitor-1 AG levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  33. Change From Baseline in Cytokeratin-18 Levels at Endpoint

    Change from baseline in cytokeratin-18 (M30 and M65) levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  34. Change From Baseline in Autotaxin Levels at Endpoint

    Change from baseline in autotaxin levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  35. C-reactive Protein Level at Endpoint

    C-reactive protein level at endpoint was reported.

    Time frame: Week 12 (Endpoint)

  36. Change From Baseline in Haptoglobin Levels at Endpoint

    Change from baseline in haptoglobin levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  37. Change From Baseline in Fibrinogen Levels at Endpoint

    Change from baseline in fibrinogen levels at endpoint was reported.

    Time frame: Baseline, Week 12 (Endpoint)

  38. Change From Baseline in 5D-Itch Scale Total Score

    5 dimensional (5D)-Itch Scale is a reliable, multidimensional measure of itching that has been validated in participants with chronic pruritus to detect changes over time. It consists of 5 domains: duration, degree, direction, disability, and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items (sleep, leisure/social, housework/errands, work/school). All items of the first four domains were measured on a 5-point Likert scale. The distribution domain included 16 potential locations of itch, including 15 body part items (head/scalp, soles, face, palms, chest, abdomen, back, buttocks, thighs, lower legs, tops of feet/toes, tops of hands/fingers, upper arms, groin, forearms) and one point of contact with clothing or bandages. Scores of each of five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritus) and 25 (most severe pruritus).

    Time frame: Baseline, Week 12 (Endpoint)

  39. Change From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score

    The VAS is a reliable and validated method of pruritus assessment. The VAS is adequate in assessing the severity of the symptom; it does not take into account other aspects of pruritus, such as the relative impact of pruritus on quality of life. The VAS, for pruritus assessment, requires the participant to use abstract thought processes to convert their itch severity to a mark on a continuum. A participant draws a line anywhere on the scale ranging from 0 to 10 (where 0 represents 'no itching' and 10 represents 'worst possible itching') that best represents the severity of participant's itching and the scoring involves manual measuring of the mark with a ruler on range of 0 to 100 millimeter (mm). Higher scores indicate worse itching.

    Time frame: Baseline, Week 12 (Endpoint)

  40. Change From Baseline in Primary Biliary Cholangitis -40 (PBC-40) Quality of Life (QoL) Questionnaire Scores

    PBC-40 QoL Questionnaire is a patient-derived, disease-specific QoL measure developed and validated for use in PBC. It consists of 9 domains with total 40 questions as: 1) digestion and diet (questions 1-3, total score range: 3-15); 2) experiences (questions 4-7, total score range: 4-20); 3) itching (questions 8-10, total score range: 3-15); 4) fatigue (questions 11-18, total score range: 8-40); 5) effort and planning (questions 19-21, total score range: 3-15); 6) memory and concentration (questions 22-27, total score range: 6-30); 7) affects you as a person (questions 28-33, total score range: 6-30); 8) affects your social life (questions 34-37, total score range: 4-20); 9) overall impact on your life (questions 38-40, total score range: 3-15). PBC-40 QoL Questionnaire has 40 questions, each scored on scale of 1-5 (1 = least impact, 5 = greatest impact). For each domain, scoring involved summing individual question response scores. Higher scores indicate poorer quality of life.

    Time frame: Baseline, Week 12 (Endpoint)

  41. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization/prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is another medically important condition. TEAEs is defined as (1) it is not present when active phase of study (time of first dose) begins and is not a chronic condition that is part of patient's medical history, or it is present at start of active phase or as part of patient's medical history, but severity/frequency increases during active phase.

    Time frame: Up to Week 12

07

Results

Posted Sep 24, 2019

Participant flow

Participant flow — Overall Study
MilestoneElafibranor 80mgElafibranor 120mgPlacebo
Started151515
Completed151415
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryRelative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint)

Relative change from baseline is in serum ALP levels at Week 12 (endpoint) were reported. Relative change from baseline is defined as percentage (%) change from baseline to endpoint.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · Percent change
Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint)
Percent changeElafibranor 80mgElafibranor 120mgPlacebo
Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint)-48.264 ± 14.7676-40.640 ± 17.36243.190 ± 14.8059
Statistical analysis
  • Elafibranor 80mg vs Placebo · ANCOVA · p = <0.001 · Difference in percentage: -52.0 · 95% CI -62.5 to -41.5
  • Elafibranor 120mg vs Placebo · ANCOVA · p = <0.001 · Difference in percentage: -43.9 · 95% CI -55.7 to -32.1
SecondaryPercentage of Participants With Response Defined by Composite Risk Scores (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] Within Normal Limits at Endpoint, and Greater Than [>] 15% ALP Reduction From Baseline to Endpoint)

Percentage of participants with response defined by Composite Risk Scores (ALP Less than \[\<\] 1.67 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 15% ALP reduction from baseline to Endpoint) was reported.

Time frame:
Up to Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined by Composite Risk Scores (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] Within Normal Limits at Endpoint, and Greater Than [>] 15% ALP Reduction From Baseline to Endpoint)
Percentage of participantsElafibranor 80mgElafibranor 120mgPlacebo
Percentage of Participants With Response Defined by Composite Risk Scores (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] Within Normal Limits at Endpoint, and Greater Than [>] 15% ALP Reduction From Baseline to Endpoint)66.778.66.7
SecondaryPercentage of Participants With Response Defined by Composite Risk Scores (ALP < 2 * Upper Limit of Normal at Endpoint, Total Bilirubin Within Normal Limits at Endpoint, and > 40% ALP Reduction From Baseline to Endpoint)

Percentage of participants with response defined by composite risk scores (ALP \< 2 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 40% ALP reduction from baseline to endpoint) was reported.

Time frame:
Up to Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined by Composite Risk Scores (ALP < 2 * Upper Limit of Normal at Endpoint, Total Bilirubin Within Normal Limits at Endpoint, and > 40% ALP Reduction From Baseline to Endpoint)
Percentage of participantsElafibranor 80mgElafibranor 120mgPlacebo
Percentage of Participants With Response Defined by Composite Risk Scores (ALP < 2 * Upper Limit of Normal at Endpoint, Total Bilirubin Within Normal Limits at Endpoint, and > 40% ALP Reduction From Baseline to Endpoint)73.342.90
SecondaryPercentage of Participants With Response Based on PARIS I Risk Score at Endpoint

Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (\<=) 3 \* ULN and aspartate aminotransferase (AST) \<= 2 \* ULN and bilirubin within normal limits.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Based on PARIS I Risk Score at Endpoint
Percentage of participantsElafibranor 80mgElafibranor 120mgPlacebo
Percentage of Participants With Response Based on PARIS I Risk Score at Endpoint80.078.653.3
SecondaryPercentage of Participants With Response Based on PARIS II Risk Score at Endpoint

Percentage of participants with response based on Paris II risk score was defined as ALP \<= 1.5 \* ULN and AST \<= 1.5 \* ULN and bilirubin within normal limits.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Based on PARIS II Risk Score at Endpoint
Percentage of participantsElafibranor 80mgElafibranor 120mgPlacebo
Percentage of Participants With Response Based on PARIS II Risk Score at Endpoint53.350.00
SecondaryPercentage of Participants With Response Based on Toronto I Risk Score at Endpoint

Percentage of participants with response based on Toronto I risk score was defined as ALP \<= 1.67 \*ULN.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Based on Toronto I Risk Score at Endpoint
Percentage of participantsElafibranor 80mgElafibranor 120mgPlacebo
Percentage of Participants With Response Based on Toronto I Risk Score at Endpoint66.778.66.7
SecondaryPercentage of Participants With Response Based on Toronto II Risk Score at Endpoint

Percentage of participants with response based on Toronto II risk scores was defined as ALP \<= 1.75 \* ULN.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Based on Toronto II Risk Score at Endpoint
Percentage of participantsElafibranor 80mgElafibranor 120mgPlacebo
Percentage of Participants With Response Based on Toronto II Risk Score at Endpoint66.778.66.7
SecondaryMedian Percentage Risk as Assessed by United Kingdom-Primary Biliary Cholangitis (UK-PBC) Risk Total Score at Endpoint

UK-PBC risk score at endpoint estimated that the median percentage risk that a participant treated with ursodeoxycholic acid (UDCA) will develop liver failure requiring liver transplant in 5, 10 and 15 years. UK-PBC score was calculated at each of the 3 survivor functions 1-baseline survival function\^exp(0.0287854\*\[alpEPxuln-1.722136304\] - 0.0422873\*\[{(altastEPxuln/10)\^-1} - 8.675729006\] + 1.4199 \* \[ln{bilEPxuln /10}+2.709607778\] -1.960303\*\[albxlln -1.17673001\]-0.4161954\*\[ pltxlln -1.873564875\]). Where: Baseline survivor function=0. 982 (at 5 years); 0. 941 (at 10 years); 0.893 (at 15 years). alpEPxuln = ALP at endpoint/upper level normal ALP; altastEPxuln=(ALT, AST) at endpoint/upper level normal of the value; bilEPxuln=bilirubin at endpoint/upper level normal bilirubin; albxlln=albumin at baseline/albumin lower level normal; pltxlln=platelet count at baseline/ platelet count lower level normal.

Time frame:
At Week 12 (Endpoint)
Reported as:
Median · Percentage risk
Median Percentage Risk as Assessed by United Kingdom-Primary Biliary Cholangitis (UK-PBC) Risk Total Score at Endpoint
Percentage riskElafibranor 80mgElafibranor 120 mgPlacebo
5 year risk at Week 120.80 (0.1 to 6.0)0.95 (0.2 to 5.8)1.30 (0.1 to 3.7)
10 year risk at Week 122.60 (0.3 to 18.8)3.05 (0.8 to 18.1)4.40 (0.5 to 12.0)
15 year risk at Week 124.70 (0.6 to 32.1)5.55 (1.5 to 31.0)8.00 (0.9 to 21.1)
SecondaryPercentage of Participants With Response Defined by 10, 20 and 40 Percent Reduction in Alkaline Phosphatase

Percentage of participants with response (defined by at least 10%, 20%, and 40% decrease in ALP from baseline to Endpoint) reported.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined by 10, 20 and 40 Percent Reduction in Alkaline Phosphatase
Percentage of participantsElafibranor 80 mgElafibranor 120 mgPlacebo
10 Percent Reduction93.392.913.3
20 Percent Reduction93.392.96.7
40 Percent Reduction86.757.10
SecondaryPercentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Endpoint

The response was defined by normalized ALP levels (ALP ULN 105 units per liter \[U/L\] for females, 129 U/L for males) at endpoint.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Endpoint
Percentage of participantsElafibranor 80 mgElafibranor 120 mgPlacebo
Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Endpoint13.321.40
SecondaryPercentage of Participants With Response Defined by Normalized Bilirubin (BIL) at Endpoint

The response was defined by normalized BIL levels (BIL ULN \<1.20 milligram per deciliter \[mg/dL\]) at endpoint.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined by Normalized Bilirubin (BIL) at Endpoint
Percentage of participantsElafibranor 80 mgElafibranor 120 mgPlacebo
Percentage of Participants With Response Defined by Normalized Bilirubin (BIL) at Endpoint86.792.993.3
SecondaryPercentage of Participants With Response Defined by Normalized Albumin (ALB) Levels at Endpoint

The response was defined by normalized ALB levels (3.5-5.2 gram per deciliter \[g/dL\] for ages 18-60 years; 3.2-4.6 g/dL for ages 61-91 years) at endpoint.

Time frame:
At Week 12 (Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants With Response Defined by Normalized Albumin (ALB) Levels at Endpoint
Percentage of participantsElafibranor 80 mgElafibranor 120 mgPlacebo
Percentage of Participants With Response Defined by Normalized Albumin (ALB) Levels at Endpoint100100100
SecondaryChange From Baseline in Alanine Aminotransferase (ALT) Levels at Endpoint

Change from baseline in ALT levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Endpoint
U/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Endpoint-0.5 ± 57.387.3 ± 29.13-1.2 ± 8.57
SecondaryChange From Baseline in Aspartate Aminotransferase (AST) Levels at Endpoint

Change from baseline in AST levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · U/L
Change From Baseline in Aspartate Aminotransferase (AST) Levels at Endpoint
U/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Aspartate Aminotransferase (AST) Levels at Endpoint6.0 ± 55.2911.1 ± 27.96-4.3 ± 7.97
SecondaryChange From Baseline in Gamma-glutamyl Transferase (GGT) Levels at Endpoint

Change from baseline in GGT levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · U/L
Change From Baseline in Gamma-glutamyl Transferase (GGT) Levels at Endpoint
U/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Gamma-glutamyl Transferase (GGT) Levels at Endpoint-91.5 ± 95.30-61.9 ± 70.820.6 ± 54.40
SecondaryChange From Baseline in 5 Prime (') Nucleotidase Levels at Endpoint

Change from baseline in 5' nucleotidase levels at endpoint was reported. 5' nucleotidase is an enzyme used as a biomarker of hepatobiliary cholestasis and is less sensitive but more specific than GGT and ALP.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · U/L
Change From Baseline in 5 Prime (') Nucleotidase Levels at Endpoint
U/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in 5 Prime (') Nucleotidase Levels at Endpoint-7.81 ± 8.279-4.59 ± 13.067-0.47 ± 3.491
SecondaryChange From Baseline in Total Bilirubin (BIL) Levels at Endpoint

Change from baseline in total BIL levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · micromole per liter (mcmol/L)
Change From Baseline in Total Bilirubin (BIL) Levels at Endpoint
micromole per liter (mcmol/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Total Bilirubin (BIL) Levels at Endpoint-0.23 ± 3.425-0.51 ± 2.821-0.01 ± 3.548
SecondaryChange From Baseline in Conjugated Bilirubin Levels at Endpoint

Change from baseline in conjugated bilirubin levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · mcmol/L
Change From Baseline in Conjugated Bilirubin Levels at Endpoint
mcmol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Conjugated Bilirubin Levels at Endpoint0.34 ± 2.229-0.06 ± 0.5960.45 ± 1.526
SecondaryChange From Baseline in Albumin Levels at Endpoint

Change from baseline in albumin levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · gram per liter (g/L)
Change From Baseline in Albumin Levels at Endpoint
gram per liter (g/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Albumin Levels at Endpoint2.2 ± 2.542.3 ± 2.730.0 ± 2.20
SecondaryChange From Baseline in Cholesterol Levels at Endpoint

Change from baseline in cholesterol levels at endpoints was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · millimole per liter (mmol/L)
Change From Baseline in Cholesterol Levels at Endpoint
millimole per liter (mmol/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Cholesterol Levels at Endpoint-0.455 ± 0.7479-0.387 ± 0.63080.043 ± 0.3706
SecondaryChange From Baseline in Low-density Lipoprotein (LDL) Cholesterol Levels at Endpoint

Change from baseline in LDL-cholesterol at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · mmol/L
Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol Levels at Endpoint
mmol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol Levels at Endpoint-0.366 ± 0.5919-0.334 ± 0.48480.061 ± 0.3272
SecondaryChange From Baseline in High-density Lipoprotein (HDL) Cholesterol Levels at Endpoint

Change from baseline in HDL-cholesterol levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · mmol/L
Change From Baseline in High-density Lipoprotein (HDL) Cholesterol Levels at Endpoint
mmol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in High-density Lipoprotein (HDL) Cholesterol Levels at Endpoint-0.017 ± 0.38980.059 ± 0.3391-0.007 ± 0.2988
SecondaryChange From Baseline in Triglycerides Levels at Endpoint

Change from baseline in triglycerides levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · mmol/L
Change From Baseline in Triglycerides Levels at Endpoint
mmol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Triglycerides Levels at Endpoint-0.155 ± 0.3460-0.253 ± 0.2085-0.019 ± 0.3776
SecondaryChange From Baseline in Total Free Bile Acid Levels at Endpoint

Change from baseline in total free bile acid levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · 10^-9 mole per liter (mol/L)
Change From Baseline in Total Free Bile Acid Levels at Endpoint
10^-9 mole per liter (mol/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Total Free Bile Acid Levels at Endpoint-248.88 ± 2496.672-673.71 ± 2962.097-135.20 ± 6777.727
SecondaryChange From Baseline in Total Conjugated Bile Acid Levels at Endpoint

Change from baseline in total conjugated bile acid levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · 10^-9 mol/L
Change From Baseline in Total Conjugated Bile Acid Levels at Endpoint
10^-9 mol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Total Conjugated Bile Acid Levels at Endpoint5008.99 ± 17844.304-3280.16 ± 10941.7691873.22 ± 21795.349
SecondaryChange From Baseline in Total Bile Acid Levels at Endpoint

Change from baseline in total bile acid levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · 10^-9 mol/L
Change From Baseline in Total Bile Acid Levels at Endpoint
10^-9 mol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Total Bile Acid Levels at Endpoint4760.11 ± 18919.661-3953.86 ± 12008.6201738.02 ± 26521.746
SecondaryChange From Baseline in 7 Alpha-hydroxy-4-cholesten-3-one Levels at Endpoint

Change from baseline in 7 alpha-hydroxy-4-cholesten-3-one levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · 10^-9 mol/L
Change From Baseline in 7 Alpha-hydroxy-4-cholesten-3-one Levels at Endpoint
10^-9 mol/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in 7 Alpha-hydroxy-4-cholesten-3-one Levels at Endpoint-16.29 ± 27.584-10.04 ± 28.6065.22 ± 10.848
SecondaryChange From Baseline in Fibroblast Growth Factor-19 Levels at Endpoint

Change from baseline in fibroblast growth factor-19 levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · nanogram per liter (ng/L)
Change From Baseline in Fibroblast Growth Factor-19 Levels at Endpoint
nanogram per liter (ng/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Fibroblast Growth Factor-19 Levels at Endpoint-21.67 ± 52.588-16.96 ± 38.933-47.08 ± 69.560
SecondaryChange From Baseline in Immunoglobulin M (IgM) Levels at Endpoint

Change from baseline in IgM levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · g/L
Change From Baseline in Immunoglobulin M (IgM) Levels at Endpoint
g/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Immunoglobulin M (IgM) Levels at Endpoint-0.339 ± 0.5846-0.472 ± 0.5507-0.076 ± 0.7227
SecondaryChange From Baseline in Tumor Necrosis Factor Levels at Endpoint

Change from baseline in tumor necrosis factor levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · ng/L
Change From Baseline in Tumor Necrosis Factor Levels at Endpoint
ng/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Tumor Necrosis Factor Levels at Endpoint0.066 ± 0.78290.154 ± 1.13740.053 ± 0.8329
SecondaryChange From Baseline in Transforming Growth Factor Beta Levels at Endpoint

Change from baseline in transforming growth factor beta levels at endpoint was reported,

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · ng/L
Change From Baseline in Transforming Growth Factor Beta Levels at Endpoint
ng/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Transforming Growth Factor Beta Levels at Endpoint734.7 ± 2103.75297.2 ± 2762.61-1163.0 ± 4295.49
SecondaryChange From Baseline in Interleukin 6 Levels at Endpoint

Change from baseline in interleukin 6 levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · ng/L
Change From Baseline in Interleukin 6 Levels at Endpoint
ng/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Interleukin 6 Levels at Endpoint-0.021 ± 0.8337-0.261 ± 0.5213-0.165 ± 0.5624
SecondaryChange From Baseline in Plasminogen Activator Inhibitor-1 Antigen (AG) Levels at Endpoint

Change from baseline in plasminogen activator inhibitor-1 AG levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · microgram per liter (mcg/L)
Change From Baseline in Plasminogen Activator Inhibitor-1 Antigen (AG) Levels at Endpoint
microgram per liter (mcg/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Plasminogen Activator Inhibitor-1 Antigen (AG) Levels at Endpoint-0.483 ± 2.9839-1.739 ± 4.6587-1.456 ± 4.6448
SecondaryChange From Baseline in Cytokeratin-18 Levels at Endpoint

Change from baseline in cytokeratin-18 (M30 and M65) levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · picomole per liter (pmol/L)
Change From Baseline in Cytokeratin-18 Levels at Endpoint
picomole per liter (pmol/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
Cytokeratin-18 M3026.12 ± 472.247163.33 ± 499.50017.93 ± 307.531
Cytokeratin-18 M65114.31 ± 627.068238.97 ± 611.520-53.16 ± 131.934
SecondaryChange From Baseline in Autotaxin Levels at Endpoint

Change from baseline in autotaxin levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · mcg/L
Change From Baseline in Autotaxin Levels at Endpoint
mcg/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Autotaxin Levels at Endpoint4.6 ± 156.9249.9 ± 77.2535.1 ± 161.58
SecondaryC-reactive Protein Level at Endpoint

C-reactive protein level at endpoint was reported.

Time frame:
Week 12 (Endpoint)
Reported as:
Geometric mean · milligram per liter (mg/L)
C-reactive Protein Level at Endpoint
milligram per liter (mg/L)Elafibranor 80 mgElafibranor 120 mgPlacebo
C-reactive Protein Level at Endpoint2.74 (1.81 to 4.14)2.84 (1.68 to 4.78)4.01 (2.52 to 6.37)
SecondaryChange From Baseline in Haptoglobin Levels at Endpoint

Change from baseline in haptoglobin levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · g/L
Change From Baseline in Haptoglobin Levels at Endpoint
g/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Haptoglobin Levels at Endpoint-0.265 ± 0.4271-0.254 ± 0.10880.025 ± 0.2244
SecondaryChange From Baseline in Fibrinogen Levels at Endpoint

Change from baseline in fibrinogen levels at endpoint was reported.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · g/L
Change From Baseline in Fibrinogen Levels at Endpoint
g/LElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Fibrinogen Levels at Endpoint-0.865 ± 0.9472-0.452 ± 0.5780-0.072 ± 1.0936
SecondaryChange From Baseline in 5D-Itch Scale Total Score

5 dimensional (5D)-Itch Scale is a reliable, multidimensional measure of itching that has been validated in participants with chronic pruritus to detect changes over time. It consists of 5 domains: duration, degree, direction, disability, and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items (sleep, leisure/social, housework/errands, work/school). All items of the first four domains were measured on a 5-point Likert scale. The distribution domain included 16 potential locations of itch, including 15 body part items (head/scalp, soles, face, palms, chest, abdomen, back, buttocks, thighs, lower legs, tops of feet/toes, tops of hands/fingers, upper arms, groin, forearms) and one point of contact with clothing or bandages. Scores of each of five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritus) and 25 (most severe pruritus).

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · Units on a scale
Change From Baseline in 5D-Itch Scale Total Score
Units on a scaleElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in 5D-Itch Scale Total Score-2.1 ± 5.15-0.1 ± 2.190.8 ± 4.93
SecondaryChange From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score

The VAS is a reliable and validated method of pruritus assessment. The VAS is adequate in assessing the severity of the symptom; it does not take into account other aspects of pruritus, such as the relative impact of pruritus on quality of life. The VAS, for pruritus assessment, requires the participant to use abstract thought processes to convert their itch severity to a mark on a continuum. A participant draws a line anywhere on the scale ranging from 0 to 10 (where 0 represents 'no itching' and 10 represents 'worst possible itching') that best represents the severity of participant's itching and the scoring involves manual measuring of the mark with a ruler on range of 0 to 100 millimeter (mm). Higher scores indicate worse itching.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · Units on a scale
Change From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score
Units on a scaleElafibranor 80 mgElafibranor 120 mgPlacebo
Change From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score-4.4 ± 22.80-4.7 ± 11.819.3 ± 35.93
SecondaryChange From Baseline in Primary Biliary Cholangitis -40 (PBC-40) Quality of Life (QoL) Questionnaire Scores

PBC-40 QoL Questionnaire is a patient-derived, disease-specific QoL measure developed and validated for use in PBC. It consists of 9 domains with total 40 questions as: 1) digestion and diet (questions 1-3, total score range: 3-15); 2) experiences (questions 4-7, total score range: 4-20); 3) itching (questions 8-10, total score range: 3-15); 4) fatigue (questions 11-18, total score range: 8-40); 5) effort and planning (questions 19-21, total score range: 3-15); 6) memory and concentration (questions 22-27, total score range: 6-30); 7) affects you as a person (questions 28-33, total score range: 6-30); 8) affects your social life (questions 34-37, total score range: 4-20); 9) overall impact on your life (questions 38-40, total score range: 3-15). PBC-40 QoL Questionnaire has 40 questions, each scored on scale of 1-5 (1 = least impact, 5 = greatest impact). For each domain, scoring involved summing individual question response scores. Higher scores indicate poorer quality of life.

Time frame:
Baseline, Week 12 (Endpoint)
Reported as:
Mean · Units on a scale
Change From Baseline in Primary Biliary Cholangitis -40 (PBC-40) Quality of Life (QoL) Questionnaire Scores
Units on a scaleElafibranor 80 mgElafibranor 120 mgPlacebo
Digestion and Diet-0.3 ± 2.74-0.6 ± 2.24-0.6 ± 3.00
Experiences0.6 ± 2.64-1.3 ± 1.77-0.7 ± 3.69
Itching-0.9 ± 6.19-4.1 ± 6.562.1 ± 5.78
Fatigue-1.9 ± 4.10-1.4 ± 2.71-1.5 ± 5.04
Effort and Planning-0.9 ± 2.03-0.8 ± 1.31-0.9 ± 1.98
Memory and concentration0.1 ± 3.26-1.5 ± 3.33-0.5 ± 3.25
Affecting you as a Person-1.8 ± 3.78-2.5 ± 2.85-1.3 ± 3.22
Affects your Social Life1.3 ± 3.080.0 ± 1.471.4 ± 4.79
Impact on your Life-0.1 ± 3.040.6 ± 0.63-1.0 ± 3.30
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization/prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is another medically important condition. TEAEs is defined as (1) it is not present when active phase of study (time of first dose) begins and is not a chronic condition that is part of patient's medical history, or it is present at start of active phase or as part of patient's medical history, but severity/frequency increases during active phase.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events
ParticipantsElafibranor 80mgElafibranor 120mgPlacebo
TEAEs121312
Serious TEAEs020

Adverse events

Collected over Up to 16 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elafibranor 80mg13/15 (86.7%)0/15 (0%)12/15 (80%)
Elafibranor 120mg13/15 (86.7%)2/15 (13.3%)13/15 (86.7%)
Placebo12/15 (80%)0/15 (0%)12/15 (80%)
Most frequent serious events
Most frequent serious events
EventElafibranor 80mgElafibranor 120mgPlacebo
Autoimmune HepatitisHepatobiliary disorders0/151/150/15
Post Procedural StrokeInjury, poisoning and procedural complications0/151/150/15
Ischaemic StrokeNervous system disorders0/151/150/15
Most frequent other events
Showing 10 of 69
Most frequent other events
EventElafibranor 80mgElafibranor 120mgPlacebo
NauseaGastrointestinal disorders0/153/151/15
FatigueGeneral disorders1/153/150/15
Urinary Tract InfectionInfections and infestations1/153/150/15
Viral Upper Respiratory Tract InfectionInfections and infestations3/150/152/15
PruritusSkin and subcutaneous tissue disorders3/153/152/15
DiarrhoeaGastrointestinal disorders0/152/152/15
DizzinessNervous system disorders2/150/151/15
HeadacheNervous system disorders2/152/151/15
VertigoEar and labyrinth disorders1/150/150/15
Dry EyeEye disorders0/151/150/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Elafibranor 80mgElafibranor 120mgPlaceboTotal
<=18 years0000
Between 18 and 65 years13101134
>=65 years25411
Age, Continuous
Age, Continuous(Years)Elafibranor 80mgElafibranor 120mgPlaceboTotal
Mean56.5 ± 8.760.4 ± 6.960.5 ± 8.659.1 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Elafibranor 80mgElafibranor 120mgPlaceboTotal
Female14151443
Male1012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elafibranor 80mgElafibranor 120mgPlaceboTotal
Hispanic or Latino32510
Not Hispanic or Latino12131035
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elafibranor 80mgElafibranor 120mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White15151444
More than one race0000
Unknown or Not Reported0000
08

Study locations

24 sites
  • Mayo Clinic in Arizona
    Phoenix, Arizona 85054, United States
  • Schiff Center for Liver Diseases
    Miami, Florida 33136, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Piedmont Research Institute
    Atlanta, Georgia 30309, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Northwell Health Institution
    Manhasset, New York 11030, United States
  • Asheville Gastroenterology Associates
    Asheville, North Carolina 28801, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Hopital Saint-Antoine
    Paris, 75012, France
  • University Hospital Frankfurt
    Frankfurt, 60590, Germany
  • Clinic for Gastroenterology and Hepatology
    Koln, 50937, Germany
  • Johannes Gutenberg University
    Mainz, 55131, Germany
  • Liver Unit, University of Barcelona
    Barcelona, 08036, Spain
  • Hospital De La Sant Creu St. Pau
    Barcelona, 08041, Spain
  • University of Birmingham Centre for Liver Research
    Birmingham, B15 2TT, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • The Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • The Newcastle Upon Tyne Hosptials NHS Foundation Trust
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 Jun;74(6):1344-1354. doi: 10.1016/j.jhep.2021.01.013. Epub 2021 Jan 21. PubMed 33484775 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Oct 2018, 18 months.

Results were first posted in Sep 2019, 10 months after primary completion.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2017
First posted
Apr 21, 2017
StartActual
Apr 5, 2017
Primary completionActual
Oct 31, 2018
CompletionActual
Oct 31, 2018
Results first posted
Sep 24, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03124108
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Apr 21, 2017
Start date
Apr 5, 2017
Primary completion
Oct 31, 2018
Completion
Oct 31, 2018
Results posted
Sep 24, 2019
Last update
Sep 24, 2019

Study contacts

Clinical Head
study director · Genfit

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion